you for real, page-9

Hi Aj,

Well done on all your posting tonight. Unlike many, you clearly see that the positives in today's announcement outweigh the negatives by many, many multiples.

In my view, anyone who cannot see that the company is now 95% the China JV are a little blind to the realities.

Exactly a year ago we had a number of projects with the potential to give SBN a real push along - FDA approval for Oraline distribution in the US, Mexico, SiYi JV in China and roadside testing. A couple of months later we also had the Medinat and Bioscreens joint ventures.

The SiYi JV is the one project (so far) that has really come through and is now the primary focus. And for good reason. Because SiYi has responded to the opportunities with gusto and has the resources and the networks to do so. And its potential markets are massive.

The recent employment of Professor Zhen demonstrates just how close the relationship between SiYi and its largest client (MPS) has been.

Professor Zhen would not have come over to SiYi/SBL if he did not see enormous potential in the opportunity.

Remember,from the SiYi web site, that "in September, 2008, Siyi sent samples of Chinese made Product to The Test Center of Criminological Products Quality, Ministry of Public Security. The Center conducted thorough tests and find the product to be in conformation with the technical specifications and the requirements of quality control".

Professor Zhen was a drugs of abuse expert in this agency so, through the testing of Oraline, he would have gained insights into its efficacy and its market opportunities.

He now seems to backing those insights and instincts.

Make no mistake about it, China is in full swing. You only have to read today's announcement in conjunction with the new SiYi web site and all the past posts on government anti-drug policy, the new anti drug law etc.

The summary of recent achievements is impressive.

Now this month we have the commencement of field testing in 15 cities, the development of a new 'stand alone' ketamine test device (which should be easy as ketamine is included in Oraline 8), the appointment of Professor Zhen and interestingly a 'road show' presentation to Professor Zhen's past "technical expert" colleagues (nice timing that!!).

Then Jan-March we have:

1. Completion of oraline field testing

2. Preparation of regulatory and marketing plan for the new ketamine test device by SiYi

3. Chinese patent applications for the purpose of "PROMOTING THE ORALINE PRODUCT IN CHINA" i.e to markets additional to MPS (and as listed on SiYi's web site)

Then March - July we have:

1. Detailed product sales projections (for Oraline iv and the new Ketamine device) in all markets (not just MPS)

2. Final MPS regulatory approval.

All the other projects are now just 'nice-to-haves' some of which are likely to have significvant revenue streams when they get up and running (particularly Oraline iv/8 in Mexico, Oraline 8 in US and Bioscreens split cup).

But they are likely to pale into insignificance compared to China.

My bet is that the so-called delay of the plant upgrade is more to do with the fact that the planned scale of upgrade may be too small and that it is prudent to wait for the detailed forecasts in the March-June period. It may even be considered prudent to move the membrane production to China, if warranted by the numbers.

I think some posters need to put some of the 'annoying' delays into their now proper perspective (minor distractions) and see where the main game is now being played. And that's clearly in Shanghai.

And the game is now being played at a furious pace. Perhaps even enough to get Mike Fitzpatrick excited.